Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels.
Rondon
Eliseo
E
Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Venkataraman
Ramesh
R
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002423:Cause of Death; D004812:Epidemiologic Methods; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D018805:Sepsis / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects; D000093242:Interleukin-6 Inhibitors
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors; C427683:afelimomab